{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-276762","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2021-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.449295+00:00","generated_at":"2026-06-29T02:36:58.374912+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Synlogic reports positive PKU data: SYNB1618 reduces Phe, SYNB1934 shows 2x activity","bullets":["SYNB1618 showed 20% reduction in fasting plasma Phe after 14 days at 1e12 dose in Phase 2 SynPheny-1 interim analysis.","SYNB1934 demonstrated two-fold higher activity than SYNB1618 in head-to-head Phase 1 study based on biomarkers of Phe metabolism.","Safety profile consistent with prior studies: no serious AEs, no drug-related discontinuations; AEs mild-moderate GI.","Company plans to complete Phase 2 SynPheny-1 with SYNB1934 arm and prepare Phase 3 program for most promising strain in 2022.","Shares trade on Nasdaq under SYBX; data support Synthetic Biotic platform for metabolic diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-276762","json":"https://secwatch.observer/filing/0001193125-21-276762.json","markdown":"https://secwatch.observer/filing/0001193125-21-276762.md","text":"https://secwatch.observer/filing/0001193125-21-276762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000119312521276762/0001193125-21-276762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000119312521276762/d234976d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:36:58.374912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}